Literature DB >> 9875271

Inflammation and Alzheimer's disease: relationships between pathogenic mechanisms and clinical expression.

P Eikelenboom1, J M Rozemuller, F L van Muiswinkel.   

Abstract

During the past 15 years a variety of inflammatory proteins has been identified in the brains of patients with Alzheimer's disease (AD) postmortem. There is now considerable evidence that in AD the deposition of amyloid-beta (A beta) protein precedes a cascade of events that ultimately leads to a local "brain inflammatory response." Here we reviewed the evidence (i) that inflammatory mechanisms can be a part of the relevant etiological factors for AD in patients with head trauma, ischemia, and Down's syndrome; (ii) that in cerebral A beta disorders the clinical symptoms are determined to a great extent by the site of inflammation; and (iii) that a brain inflammatory response can explain some poorly understood characteristics of the clinical picture, among others the susceptibility of AD patients to delirium. The present data indicate that inflammatory processes in the brain contribute to the etiology, the pathogenesis, and the clinical expression of AD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9875271     DOI: 10.1006/exnr.1998.6920

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  16 in total

Review 1.  Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders.

Authors:  Todd E Golde
Journal:  Neuron       Date:  2019-03-20       Impact factor: 17.173

2.  Prominence of central sphingosine-1-phosphate receptor-1 in attenuating aβ-induced injury by fingolimod.

Authors:  Masoumeh Asle-Rousta; Zeynab Kolahdooz; Leila Dargahi; Abolhassan Ahmadiani; Sanaz Nasoohi
Journal:  J Mol Neurosci       Date:  2014-09-20       Impact factor: 3.444

Review 3.  A review of experimental evidence linking neurotoxic organophosphorus compounds and inflammation.

Authors:  Christopher N Banks; Pamela J Lein
Journal:  Neurotoxicology       Date:  2012-02-10       Impact factor: 4.294

Review 4.  Role of formyl peptide receptor-like 1 (FPRL1/FPR2) in mononuclear phagocyte responses in Alzheimer disease.

Authors:  Pablo Iribarren; Ye Zhou; Jinyue Hu; Yingying Le; Ji Ming Wang
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

5.  Expression of macrophage colony-stimulating factor receptor is increased in the AbetaPP(V717F) transgenic mouse model of Alzheimer's disease.

Authors:  G M Murphy; F Zhao; L Yang; B Cordell
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

6.  NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease.

Authors:  C A Colton; M P Vitek; D A Wink; Q Xu; V Cantillana; M L Previti; W E Van Nostrand; J B Weinberg; B Weinberg; H Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-14       Impact factor: 11.205

Review 7.  The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP.

Authors:  Carol A Colton; Donna M Wilcock; David A Wink; Judianne Davis; William E Van Nostrand; Michael P Vitek
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

8.  Alzheimer's disease: A hypothesis on pathogenesis.

Authors:  D Harman
Journal:  J Am Aging Assoc       Date:  2000-07

9.  The APOE4 genotype alters the response of microglia and macrophages to 17beta-estradiol.

Authors:  Candice M Brown; Emily Choi; Qing Xu; Michael P Vitek; Carol A Colton
Journal:  Neurobiol Aging       Date:  2007-06-05       Impact factor: 4.673

10.  Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases.

Authors:  Todd E Golde; Victor M Miller
Journal:  Alzheimers Res Ther       Date:  2009-10-12       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.